Stocks in Play - 17th February 2026

Today in Focus: CMPS

Sources & Services I Use in my Trading:

• Finviz - Scanning, Short Interest, Float, Fundamentals

• Tradingview - Charting & Scanning

• BiopharmaIQ - FDA Calendars & Upcoming Biotech Catalysts

• Koyfin - Fundamental Data

• Tradersync - Trade Journal

Situational Awareness

Market Condition: Below all major Moving Averages. Gap down open on the cards.

Commentary: Gap down open in QQQ and SPY. Would be bullish to see a red to green today. Sell bars have been in high volume as the rotation occurs. I’m conservative on new positions and continuing to try grind my account for now. One play today which is Biotech which could be helpful in a weak market as they tend to be disconnected.

Upcoming Earnings:
After Hours: IOSP, QUAD, MCY, LZB, ACLS, TOL, RSG, GSM, EQT
Before Open: BLCO, COCO, OSW, OGE, SEDG, DINO, PUMP

Trade Updates:

Current Positions: FSLY, GLW, STM, MPC, INNV, CGNX, NKTR, ROIV

In Play

CMPS:  Positive topline results from Phase 3 COMP006,

Key Metrics: Industry Group: Medical Care Facilities, Market Cap: 696.00M, Float: 94.23M, Short Interest: 6.59%, Days to Cover: 4.50, Sales Y/Y TTM: -, EPS Y/Y TTM: -21.62%, Earnings: Nov 04 BMO, Exchange: NASDAQ

Catalyst: Compass Pathways announced positive topline results from COMP006, its second pivotal Phase 3 trial evaluating COMP360 (synthetic psilocybin) in treatment-resistant depression (TRD). The trial met its primary endpoint: two fixed doses of COMP360 25 mg vs. 1 mg demonstrated a -3.8 point MADRS reduction (p<0.001, 95% CI [-5.8, -1.8]) at Week 6.

Some difficult pre market price action but is resolving higher closer to the open. Chart is constructive. I highlighted Psychedelics as a theme in 2026. I read some articles on Biotech push as well as Republican support for these drugs in treatments. Very strong clincial data. That is two positive trials. Has potential for a sustained run. Holds Breakthrough Therapy Designation.

CEO Kabir Nath: "This is a remarkable achievement for the field of psychiatry — especially in the TRD population, where proving benefit has historically been extraordinarily challenging." — Promotional intensity: Moderate-High, but substantiated by the actual data (two Phase 3 wins in TRD is genuinely rare)

CMO Dr. Guy Goodwin: "These results redefine rapidity and durability for TRD patients" and "this potential treatment truly stands out for its extremely rapid and sustained efficacy." — Promotional intensity: High. "Redefine" and "truly stands out" are strong claims. However, next-day onset + 26-week durability from 1-2 doses does legitimately differentiate from existing options.

Delayed Reaction/Continuation Watchlist:

Monitoring:

• ZM

• WULF

• SGML

• EGHT

• DECK

• VRT

Delayed Reaction Watchlist (TradingView Link)

Like what you're reading? Support this work via ☕ Ko-Fi.

_{Note: This is my methodology for identifying stocks in play. There are many valid approaches to trading catalysts—find the setups, timeframes, and risk parameters that align with your strategy.}